Decreased bone resorption in H1 histamine receptor antagonist treated allergic children

Szilvia Meszaros; Viktoria Ferencz; Agnes Bojszko; Eva Pallinger; Andras Falus; Eva Hosszu; Csaba Horvath

P419

Prev Next

Section Contents Cite

Endocrine Abstracts (2007) 14 P419

ECE2007 Poster Presentations (1) (659 abstracts)

Decreased bone resorption in H1 histamine receptor antagonist treated allergic children

Szilvia Meszaros ¹ , Viktoria Ferencz ¹ , Agnes Bojszko ² , Eva Pallinger ³ , Andras Falus ³ , Eva Hosszu ⁴ & Csaba Horvath ¹

Views

Author affiliations

¹1st Department of Internal Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary; ²Heim Pal Paediatric Hospital, Budapest, Hungary; ³Department of Genetics, Cell- and Immunobiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary; ⁴2nd Department of Paediatric, Faculty of Medicine, Semmelweis University, Budapest, Hungary.

Histamine receptor antagonists seem to have effect on bone metabolism according to previous studies. We investigated the bone turnover in allergic children who were treated with H1 hisztamin receptor (H1R) antagonists.

The biochemical bone turnover markers [β-CrossLapps (β-CTx), osteocalcin (OCN), β-CTx/OCN ratio], parathyroid hormone (PTH) and the 25-OH-vitamin D₃ were determined in 37 H1R antagonist treated multiplex allergic children and in 21 age and gender matched healthy children. The intracytoplasmatic histidine decarboxylase (HDC), hisztamin, and surface H1 and H2 receptors expression were assessed by flow cytometry on peripheral leukocytes. The distribution of lymphocyte subpopulation were also determined.

The serum OCN, PTH and 25-OH-vitamin D₃ levels did not differ between the healthy and the allergic groups. However, the β-CTx was lower in the H1R antagonists treated allergic children (1090.82±80.25 pg/ml) in comparison with controls (1456.58±95.81 pg/ml; P=0.006). The β-CTx/OCN ratio was found to be lower in the H1R antagonists treated allergic patients than in the controls (9.24±0.608 vs 12.65±0.53; P=0.001). β-CTx serum level correlated with OCN in the controls (r=0.845, P<0.001) and in the H1R antagonist treated allergic, too (r=0.519, P=0.005). Higher HDC expression and H1 receptor down regulation was found in allergic children. The CD3+/CD16-56+T cells were in higher rate in children of control group.

Decreased bone resorption was found among H1 receptor antagonist treated allergic children, which is indicated by serum markers. Therefore, bone turnover is shifted toward bone formation in the H1R antagonist treated allergic subjects.